No­var­tis gener­ics arm files for MS biosim­i­lar, chal­leng­ing Bio­gen; Pluris­tem short­ens name

No­var­tis’ gener­ics arm San­doz said it has sub­mit­ted ap­pli­ca­tions for a mul­ti­ple scle­ro­sis and Crohn’s dis­ease biosim­i­lar.

The drug is a biosim­i­lar for Bio­gen’s Tysabri, known gener­i­cal­ly as na­tal­izum­ab. Ac­cord­ing to San­doz, in pa­tients with re­laps­ing-re­mit­ting MS, the biosim­i­lar matched Tysabri in both ef­fi­ca­cy and safe­ty. Its BLA for the biosim­i­lar has been ac­cept­ed by both US and EU au­thor­i­ties, San­doz said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.